With the approval of the National Med¥' ical Products AdministraΩ £tion, Shanghai WD Pharma €←∞is sponsoring a Phase II clinic•↓±£al trial of WD-1603 for the trea↔$ 'tment of early-onset idiβ∑€♠opathic Parkinson's disease usi≈λε→ng "Next-Generation Carbidopa/Levo→∑≥¥dopa Controlled-Rele÷★↔©ase Tablets." The trial is bei≤&ng conducted by Huashan ↔ε♦§Hospital affiliated with Fud≠λan University, the Second Hospital aff≥☆"iliated with Soochow University, Xi∑↕∑δangya Hospital of Ce€‍ ntral South University, and the §↑First Hospital affiliated with Sun ₽λYat-sen University.